Does One Size Fit All? Considerations for Incretin Use in Special Populations

Metabolic syndrome and obesity are increasingly prevalent among persons with liver disease, particularly in those with metabolic dysfunction–associated steatotic liver disease (MASLD). As hepatologists incorporate powerful incretin therapies into their treatment arsenal, understanding their optimal use in diverse and special populations becomes essential—and is the focus of this session. Presenters discuss emerging evidence that highlights the importance of tailoring these therapies to unique patient groups including: (1) liver transplant candidates, recipients, and donors; (2) women with reproductive considerations; (3) Black, Indigenous, and People of Color (BIPOC) populations; and (4) nonobese individuals with metabolic syndrome. Speakers explore the latest insights and practical approaches for applying incretin therapies in these distinct populations, aiming to guide clinicians in personalized and effective management strategies.